Medical Management of Opioid-Induced Constipation
Publication Date: January 1, 2019
Treatment
Summary of Recommendations of AGA Clinical Guidelines for the Medical Management of OIC
Traditional laxatives
In patients with OIC, AGA recommends use of laxatives as first-line agents. ( Moderate , Strong )
612
Peripherally-acting µ-opioid receptor antagonists
In patients with laxative refractory OIC, AGA recommends naldemedine over no treatment. ( High , Strong )
612
In patients with laxative refractory OIC, AGA recommends naloxegol over no treatment. ( Moderate , Strong )
612
In patients with laxative refractory OIC, AGA suggests methylnaltrexone over no treatment. ( Low , Conditional (weak) )
612
Intestinal secretagogues
In patients with OIC, AGA makes no recommendation for the use of lubiprostone. ( Evidence Gap , No recommendation )
612
Selective 5-HT agonists
In patients with OIC, AGA makes no recommendation for the use of prucalopride. ( Evidence Gap , No recommendation )
612
Recommendation Grading
Disclaimer
Overview
Title
Medical Management of Opioid-Induced Constipation
Authoring Organization
American Gastroenterological Association
Publication Month/Year
January 1, 2019
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Target Patient Population
Adults with opioid-induced constipation
Inclusion Criteria
Male, Female, Adult, Older adult
Health Care Settings
Ambulatory, Hospital, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Treatment, Management
Diseases/Conditions (MeSH)
D000079689 - Opioid-Induced Constipation
Keywords
opioids, constipation, OIC, Opioid Induced Constipation